NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Collegium Pharmaceutical, Inc. COLL
13 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$780.6M
▲ 23.6% vs FY2024
EPS · FY25
$1.73
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
23.7%
Net margin · FY25
8.1%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 780.6M
Revenue, FY2025 · full 13-year series below
Revenue
Net income
8 cents of every revenue dollar became profit this year.
Per share
USD 1.73
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
23.7%
Return on equity, FY2025
ROE
Operating margin23.0%
Net margin8.1%
Return on assets3.8%
Each USD of equity produced 24 cents of profit this year.
Returned to shareholders
USD 20.8M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 20.8M
Share of profit33.1%
Consecutive raises—
USD 20.8M in buybacks — 33% of the year's profit went back to shareholders.
Growth
+20.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+18.9%
+20.3%
Net income
+18.6%
EPS, diluted
+17.9%
Returned to shareholders
+109.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.03B
Shares outstanding, FY2025
Change, 5 years−8.4%
Change, 10 years+52.9%
The share count shrank 8% in five years — the same company, cut into fewer, larger slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 1.7B
total assets, end of FY2025
Total assetsUSD 1.7B
EquityUSD 301.7M
CashUSD 231.3M
Current ratio1.57×
Equity funds 18% of total assets.
History
13 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Revenue $B
0.8
0.6
0.6
0.5
0.3
0.3
0.3
0.3
0.0
0.0
·
·
·
Operating income $B
0.2
0.2
0.2
0.0
0.0
0.1
−0.0
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
EBITDA $B
0.2
0.2
0.2
0.0
0.0
0.1
−0.0
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
−0.0
−0.1
0.0
0.0
·
·
·
·
·
·
Net income $B
0.1
0.1
0.0
−0.0
0.1
0.0
−0.0
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
EPS, diluted $
1.73
1.86
1.29
−0.74
1.86
0.76
−0.68
−1.19
−2.47
−3.88
−1.48
−22.72
−4.06
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
23.7
32.6
24.7
−12.6
36.8
19.6
−25.4
−40.0
−62.7
−85.6
·
·
·
Shares out B
0.03
0.03
0.03
0.03
0.03
0.03
0.03
0.03
0.03
0.03
0.02
0.00
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
42 of 45
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 3 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed